You are here
Common Antibiotic Linked to Heart Deaths
The antibiotic clarithromycin — widely used for treating common bacterial infections — is associated with an increased risk of heart deaths, finds a new study published in BMJ.
The authors — a team of Dutch researchers — say their findings require urgent confirmation, given that many millions of people are prescribed the drug each year. But they stress that the absolute risk is small and that prescribing practices should not be changed until the results have been confirmed in an independent study.
Clarithromycin belongs to a group of antibiotics known as macrolides. Macrolide antibiotics prolong the duration of electrical activity of the heart muscle (known as the QT interval) and are therefore thought to increase the risk of potentially fatal heart-rhythm problems.
Therefore, the researchers decided to assess the risk of cardiac death associated with clarithromycin and another macrolide, roxithromycin, compared with penicillin V, an antibiotic with no known cardiac risk.
Using national databases, the investigators identified more than 5 million treatment courses among Danish adults aged 40 to 74 years from 1997 to 2011 (160,297 courses with clarithromycin; 588,988 with roxithromycin; and 4,355,309 with penicillin V).
Individuals with serious disease who may be at high baseline risk of death were excluded from the analysis.
A total of 285 cardiac deaths were observed during ongoing use of the study drugs. Eighteen of these deaths occurred during the use of clarithromycin, and 32 occurred during the use of roxithromycin.
After adjusting for factors such as age, sex, baseline cardiac risk, and the use of other medications, ongoing use of clarithromycin was associated with a 76% higher risk of cardiac death compared with the use of penicillin V. There was no increased risk of cardiac death with clarithromycin after the treatment had ended.
The absolute risk difference was 37 cardiac deaths per 1 million courses with clarithromycin. No increased risk of cardiac death was found with ongoing or past use of roxithromycin.
“Our study expands on the available knowledge of the cardiac safety of macrolides, being the first large-scale population-based observational study to show significantly increased cardiac risk with clarithromycin and the relative cardiac safety of roxithromycin,” the authors reported.
They emphasized that the absolute increase in risk with clarithromycin was small and should have limited, if any, effect on prescribing practices in individual patients. However, they noted, “clarithromycin is one of the more commonly used antibiotics in many countries, and many millions of people are prescribed this drug each year; thus, the total number of excess (potentially avoidable) cardiac deaths may not be negligible.”
Before these results are used to guide clinical decision-making, “confirmation in independent populations is an urgent priority given the widespread use of macrolide antibiotics,” they concluded.